Physician profile
Nancy G Bartley
NPI 1689751828
$3,540.99
in general payments reported to CMS, 2019-2025
25 companies · $424 in 2025
The $424 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $720 · 2021: $799 · 2022: $632 · 2023: $233 · 2024: $374 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,030.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $778.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $723.40 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $383.95 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $333.26 | 2020-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $215.56 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $203.50 | 2019-2022 | |
| Astellas Pharma US INC | $122.80 | 2019-2022 | |
| Abbvie INC. | $116.68 | 2022-2024 | Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $101.89 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.09 | 2020-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $72.05 | 2020-2022 | |
| Amgen INC. | $58.01 | 2021-2024 | Repatha, Otezla |
| Inspire Medical Systems, INC. | $50.53 | 2024 | Inspire |
| Janssen Biotech, INC. | $41.10 | 2021 | |
| Sanofi-Aventis U.S. LLC | $39.80 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $34.52 | 2021-2025 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $31.60 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.65 | 2022 | |
| Axsome Therapeutics, INC. | $28.67 | 2025 | Auvelity |
| Lundbeck LLC | $23.25 | 2025 | Vyepti |
| Genentech USA, INC. | $19.92 | 2020 | |
| Sumitomo Pharma America, INC. | $18.20 | 2023 | Gemtesa |
| Intra-Sana Laboratories | $15.33 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Sanofi Pasteur INC. | $13.02 | 2020 | |
| Ascend Therapeutics US, LLC | $11.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Bartley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.